GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » EPS without NRI

Diamyd Medical AB (OSTO:DMYD B) EPS without NRI : kr-1.62 (TTM As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB EPS without NRI?

Diamyd Medical AB's earnings per share without non-recurring items for the three months ended in May. 2025 was kr-0.40. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in May. 2025 was kr-1.62.

During the past 3 years, the average earnings per share (NRI) Growth Rate was -8.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Diamyd Medical AB's EPS without NRI or its related term are showing as below:

OSTO:DMYD B' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -340.1   Med: -8.2   Max: 24.1
Current: -8.2

During the past 13 years, Diamyd Medical AB's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 24.10% per year. The lowest was -340.10% per year. And the median was -8.20% per year.

OSTO:DMYD B's 3-Year EPS without NRI Growth Rate is ranked worse than
72.99% of 1229 companies
in the Biotechnology industry
Industry Median: 12.5 vs OSTO:DMYD B: -8.20

Diamyd Medical AB's EPS (Diluted) for the three months ended in May. 2025 was kr-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in May. 2025 was kr-1.69.

Diamyd Medical AB's EPS (Basic) for the three months ended in May. 2025 was kr-0.40. Its EPS (Basic) for the trailing twelve months (TTM) ended in May. 2025 was kr-1.69.


Diamyd Medical AB EPS without NRI Historical Data

The historical data trend for Diamyd Medical AB's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB EPS without NRI Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.10 -1.14 -1.45 -1.49 -1.44

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.35 -0.47 -0.40 -0.40

Competitive Comparison of Diamyd Medical AB's EPS without NRI

For the Biotechnology subindustry, Diamyd Medical AB's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's PE Ratio without NRI falls into.


;
;

Diamyd Medical AB EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in May. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-1.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Diamyd Medical AB EPS without NRI Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines